Glenmark Pharmaceuticals Announces New Data Presentations on Ryaltris™ at the ACAAI Annual Scientific Meeting 2018

Deepthi | Myequity news | Date : 16-11-2018 18:30:00 IST


Glenmark Pharmaceuticals, a global pharmaceutical company is presenting new data for for its leading respiratory pipeline candidate Ryaltris™ (rye - al’ - tris) (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2018 (ACAAI 2018) in Seattle, Washington. Ryaltris is an investigational fixed-dose combination nasal spray intended for the treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older. “Ryaltris” has been conditionally accepted by the FDA as the brand name.



About Glenmark Pharmaceuticals


Glenmark Pharmaceuticals Ltd. (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries. Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology.
 


More from Myequity